Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States

Clinical Therapeutics

Volumn 37, Issue 8, 2015, Pages 1713-1725.e3

  Le, T Kim ^a   MacAulay, Dendy ^b   Kalsekar, Anupama ^a   Yuan, Yong ^a   Sorg, Rachael A ^b   Wei, Jin ^b   Wu, Eric Q ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

anemia; CHC; cost; DAA; rash; resource utilization

Indexed keywords

ANTIHISTAMINIC AGENT; BOCEPREVIR; CALAMINE; CORTICOSTEROID; TELAPREVIR; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; RIBAVIRIN;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DERMATOLOGIST; DRUG COST; DRUG ERUPTION; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HEMATOLOGIST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTPATIENT; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG ERUPTIONS; ECONOMICS; FACTUAL DATABASE; HEALTH CARE COST; HEALTH CARE PLANNING; HEPATITIS C, CHRONIC; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; DATABASES, FACTUAL; DRUG COSTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; RIBAVIRIN; UNITED STATES;

EID: 84940608471     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.05.503     Document Type: Article

References (24)

1. G.L. Armstrong, A. Wasley, E.P. Simard, and et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714
2. D. Conte, M. Fraquelli, D. Prati, and et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women Hepatology 31 2000 751 755
3. Centers for Disease Control and Prevention. Hepatitis C FAQs for the Public. http://www.cdc.gov/hepatitis/c/cfaq.htm. Accessed 28 October 2014.
4. E. Chak, A.H. Talal, K.E. Sherman, and et al. Hepatitis C virus infection in USA: an estimate of true prevalence Liver Int 31 2011 1090 1101
5. M. Wise, S. Bialek, L. Finelli, and et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004 Hepatology 47 2008 1128 1135
6. M.W. Fried, M.L. Shiffman, K.R. Reddy, and et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
7. A. Craxi, and A. Licata Clinical trial results of peginterferons in combination with ribavirin Semin Liver Dis 23 Suppl. 1 2003 35 46
8. S.J. Hadziyannis, H. Sette Jr, T.R. Morgan, and et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
9. Y. Iwasaki, Y. Araki, H. Ikeda, and et al. Predictive factors for dose modification and premature discontinuation of interferon plus ribavirin for adverse effects in Japanese patients with chronic hepatitis C Gastroenterology 124 Suppl. 1 2003 A780
10. M.W. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 Suppl. 1 2002 S237 S244
11. B.R. Bacon, S.C. Gordon, E. Lawitz, and et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
12. F. Poordad, J. McCone Jr, B.R. Bacon, and et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
13. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, and et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
14. S. Zeuzem, P. Andreone, S. Pol, and et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
15. M.G. Ghany, D.R. Nelson, D.B. Strader, and et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
16. B.R. Bacon, S.C. Gordon, E. Lawitz, and et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
17. H. Montaudié, T. Passeron, N. Cardot-Leccia, and et al. Drug rash with eosinophilia and systemic symptoms due to telaprevir Dermatology 221 2010 303 305
18. X. Gao, J.M. Stephens, J.A. Carter, and et al. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C Expert Rev Pharmacoecon Outcomes Res 12 2012 335 343
19. U.S. Food and Drug Administration (FDA) News Release. FDA approves first combination pill to treat hepatitis C. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm. Accessed December 9, 2014.
20. R.A. Deyo, D.C. Cherkin, and M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613 619
21. M.S. Sulkowski, F. Poordad, M.P. Manns, and et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial Hepatology 57 2013 974 984
22. P. Cacoub, M. Bourlière, J. Lübbe, and et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals J Hepatol 56 2012 455 463
23. S. Sapra, E. Chang, M.S. Broder, and G. L'Italien Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Serv Res 14 2014 429
24. A. Osinusi, E.G. Meissner, Y.J. Lee, and et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811